Atossa Therapeutics: CEO Buy‑Back & Options Boost Confidence Ahead of ATC‑305 Milestone
Atossa Therapeutics insider buys and stock‑option grants signal confidence; the firm’s antibody therapies (ATC‑201, ATC‑305) show early promise, fast‑track FDA status, and potential upside despite current price volatility.
4 minutes to read